Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.
These two pharma stocks all have upside of over 100% say top Wall Street analysts.
Global Blood Therapeutics Inc (NASDAQ:GBT) shares rose about 9% today after the biopharmaceutical company initiated a Phase 1 trial evaluating GBT440 in healthy volunteers under hypoxic …
Roth Capital analyst Mark Breidenbach is out today with a favorable report on shares of Global Blood Therapeutics Inc (NASDAQ:GBT), after the company provided updated …
Today, Global Blood Therapeutics Inc (NASDAQ:GBT) announced design of the pivotal two-part GBT-440 Phase III HOPE trial in evaluating adults and adolescents with …
